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Abstract: In renal failure, the systemic accumulation of uremic waste products is strongly 
associated with the development of a chronic inflammatory state. Here, the effect of 
cationic uremic toxins on the release of inflammatory cytokines and endothelin-1 (ET-1) 
was investigated in conditionally immortalized proximal tubule epithelial cells (ciPTEC). 
Additionally, we examined the effects of ET-1 on the cellular uptake mediated by organic 
cation transporters (OCTs). 
Exposure of ciPTEC to cationic uremic toxins initiated production of the inflammatory 
cytokines IL-6 (117 ± 3%, p < 0.001), IL-8 (122 ± 3%, p < 0.001), and ET-1 (134 ± 5%,  
p < 0.001). This was accompanied by a down-regulation of OCT mediated 4-(4-
(dimethylamino)styryl)-N-methylpyridinium-iodide (ASP+) uptake in ciPTEC at 30 min  
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(23 ± 4%, p < 0.001), which restored within 60 min of incubation. Exposure to ET-1 for 24 h 
increased the ASP+ uptake significantly (20 ± 5%, p < 0.001). These effects could be 
blocked by BQ-788, indicating activation of an ET-B-receptor-mediated signaling pathway. 
Downstream the receptor, iNOS inhibition by (N(G)‐monomethyl‐l‐arginine) L-NMMA 
acetate or aminoguanidine, as well as protein kinase C activation, ameliorated the short-
term effects. 
These results indicate that uremia results in the release of cytokines and ET-1 from 
human proximal tubule cells, in vitro. Furthermore, ET-1 exposure was found to regulate 
proximal tubular OCT transport activity in a differential, time-dependent, fashion.  
Keywords: uremic toxins; endothelin signaling; cytokines; organic cation transport; iNOS; 
protein kinase C 
 
1. Introduction 
Renal transport processes are essential for the maintenance of body homeostasis. In the kidney, 
clearance of exogenous compounds and endogenous waste products from the circulation is facilitated 
by both glomerular filtration and active tubular secretion. The proximal tubule basolateral membrane 
transporters are responsible for the uptake of substrates from the circulation, while the apical 
transporters present in the proximal tubule facilitate their subsequent urinary release. In patients 
suffering from chronic kidney disease (CKD) or end-stage renal disease (ESRD), insufficient renal 
clearance and the subsequent accumulation of waste products lead to the development of uremia. 
Many solutes that accumulate in uremia have been identified [1]. However, we have only just begun to 
understand the effects that these compounds can exert on biological processes and their influence in 
the development of secondary morbidities. Previously, we demonstrated competitive inhibition of a 
selection of cationic uremic toxins (UTs) on organic cation uptake in a human conditionally 
immortalized proximal tubule epithelial cell model (ciPTEC) that endogenously expresses various 
renal transport proteins [2,3]. The clearance of cationic UTs (polyamines, guanidines and acrolein) 
largely depends on tubular secretion due to their high protein binding and/or compartmentalization [4,5]. 
In renal failure, the accumulation of these solutes is associated with inflammation, cardiovascular 
morbidity and perturbed erythropoiesis [6–8]. Moreover, conventional (hemo) dialysis methods are 
insufficient for their removal. 
The development of a chronic inflammatory state is common in renal patients, and uremia has been 
identified as an important causative factor [9]. Increased levels of the vasoactive peptide endothelin-1 
(ET-1), and pro-inflammatory cytokines such as IL-6, IL-8, and TNFα have been observed both before 
and after the start of dialysis therapy [10–14]. IL-6 promotes various inflammatory events, including 
the activation of lymphocytes, and is identified as a strong pro-fibrotic factor. Both IL-6 and IL-8 
levels are correlated with increased mortality and poor disease outcome in renal failure [15]. TNFα is 
also known as an important factor in the development of renal fibrosis, and induces the production of 
additional inflammatory mediators such as ET-1 [16–18]. 
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In healthy subjects, ET-1 functions as a potent peptide regulating the vascular tone, blood flow, and 
water and salt homeostasis. In the nephron, ET-1 mediates these processes through its tight regulatory 
effect on intracellular calcium, sodium and chloride channels, the production of phospho kinases and 
nitric oxide (NO) [19]. However, in patients suffering from renal disease, increased systemic ET-1 
levels are also linked to a decline in renal function, the development of interstitial fibrosis, proteinuria, 
cardiomyopathy and glomerulosclerosis [20–22]. Our laboratory has previously demonstrated that 
exposure to nephrotoxicants can induce an ET-1-mediated signaling cascade in the proximal tubule. 
Upon stimulation, the proximal tubule produces ET-1 which can lead to activation of regulatory 
pathways including NOS and protein kinase C (PKC), ultimately resulting in a reduction of efflux 
transport mediated by two apical membrane transporters P-glycoprotein (P-gp) and multidrug 
resistance protein 2 (MRP2) [23–25]. On the other hand, long-term exposures resulted in an 
upregulation of the transport proteins, accompanied by nephroprotection [26,27]. 
In the present study, we investigated if a selection of cationic UTs, which were previously shown to 
interfere with tubular organic cation uptake, can act as nephrotoxicants and induce the local production 
of inflammatory mediators. Furthermore, we investigated if ET-1 can regulate the uptake of cationic 
compounds in human renal proximal tubule epithelial cells. To this end, the production of IL-6, IL-8, 
TNFα and ET-1 were assessed, and the short- and long-term effects of ET-1 on the regulation of 
organic cation influx transport in the human renal cell model were studied. 
2. Experimental Section  
2.1. Chemicals 
Spermine, spermidine, cadaverine, putrescine dihydrochloride, acrolein, guanidine hydrochloride, 
methylguanidine hydrochloride, and 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) 
were purchased from Invitrogen (Eugene, OR, USA). Tetrapentylammoniumchloride (TPA), insulin, 
transferrine, selenium, tri-iodothyronine, hydrocortisone, epidermal growth factor, Endothelin-1 (ET-1), 
BQ788, aminoguanidine (AG), and 8-Br-cGMP were purchased from Sigma-Aldrich Co. 
(Zwijndrecht, Netherlands). Sn-1,2-dioctanoyl glycerol (DOG) was obtained from Enzo Life-sciences 
(Raamsdonksveer, Netherlands). N(G)‐monomethyl‐l‐arginine (L-NMMA) acetate was purchased from 
Tocris bioscience (Bristol, UK) 
2.2. Cell Culture 
A previously developed and characterized immortalized human proximal tubule epithelial cell line, 
ciPTEC, obtained from a healthy volunteer urine samples [3,28] was cultured in Dulbecco’s modified 
eagle medium DMEM-HAM’s F12 (Lonza; Basel, Switzerland) containing 10% v/v fetal calf serum 
(FCS) (Greiner Bio-One; Alphen a/d Rijn, the Netherlands), 5 µg·mL−1 insulin, 5 µg·mL−1 transferrine,  
5 ng·mL−1 selenium, 36 ng·mL−1 hydrocortisone, 10 ng·mL−1 epidermal growth factor and 40 pg·mL−1 
tri-iodothyronine. CiPTEC were in culture for up to 40 passages, no antibiotics or phenol red was 
present during this time. Since the cell model was established after immortalization using hTERT and 
the temperature sensitive SV40t oncogenes, the cells proliferate at 33 °C and differentiate at 37 °C 
culture conditions [3]. Regular culture was performed at 33 °C 5% (v/v) CO2, media was refreshed 
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every 2/3 days. For experiments, cells were seeded at a density of 1:3 and left to attach for 24 h at 33 °C. 
Subsequently, the cells were transferred to 37 °C to mature for 7 days prior to the experiments. 
2.3. Enzyme-Linked Immuno Sorbent Assays 
To quantify the production of IL-6, IL-8, and TNFα or ET-1 by ciPTEC under various culture 
conditions Enzyme-Linked Immuno Sorbent Assays (ELISAs) were performed. DuoSet® ELISA 
Development Systems; IL-6 #DY206, IL-8 #DY208, TNFα #DY210, ET-1 #DY1160 (R&D systems, 
Abingdon, UK) were used to accurately measure these compounds in complete culture medium 
supernatant. For all assays, 500 µL of media of exposed cells was harvested after the designated 
incubation period. The samples were centrifuged for 5 min at 7500 × g and the supernatant stored at 
−20 °C for a maximum of 2 months. For IL-6 and IL-8 the samples were diluted 500 times in 
phosphate buffered saline (PBS) or reagent diluent (PBS + 1% v/v FCS), respectively. The samples for 
TNFα and ET-1 were diluted 5× and 10× in PBS, respectively. The assays were subsequently 
performed according to the manufacturers’ protocol. The optical density of each well was measured 
immediately using the VictorX multilable plate reader (PerkinElmer, Waltham, MA, USA) set to 460 nm. 
To correct for optical imperfections in the plate, the readings at 540 nm were subtracted from these 
measurements. 
Additionally, we tested the effect of a combination of cationic UTs on cytokines and ET-1 
production. To mimic uremic conditions, a mixture of toxins was used comparable to 10 or 1 times the 
uremic plasma concentrations reported in literature; viz. spermidine 0.67 µM, spermine 0.09 µM, 
cadaverine 0.21 µM, putrescine 0.88 µM, acrolein 1.42 µM, guanidine 2.18 µM, and methylguanidine 
7.66 µM [29–32]. 
2.4. qPCR 
Total RNA was isolated using TRIzol (Life Technologies Europe BV, Zoetermeer, The Netherlands) 
and chloroform extraction according to the manufacturers’ protocol. 2 μg of total RNA served as a 
template for single-strand cDNA synthesis in a reaction using oligo (dT) and random primers in a  
M-MLV reverse transcriptase reaction mixture (Catalog #28025-013, Invitrogen, Bleiswijk, 
Netherlands) according to the manufacturers’ protocol (Doc. Rev: 100702). The mRNA expression 
levels were detected using gene specific primer-probe sets (Hs00174961_m1; Applied Biosystems, 
Foster City, CA, USA) and TaqMan Universal PCR Master Mix (Applied Biosystems). The CFX96 
Real Time PCR system (Bio-Rad Laboratories, Veenendaal, Netherlands) was used to perform the 
qPCR reactions and data was analyzed using the CFX ManagerTM software (Bio-Rad Laboratories). 
The reference gene GAPDH was used to normalize the mRNA expression levels. Data are expressed 
as fold increase compared to proliferating ciPTEC. 
2.5. OCT Mediated ASP+ Uptake 
CiPTEC were cultured until confluence, in glass bottom Petri dish as described above. Cells were 
exposed to 100 nM ET-1 for 24 h, 30 min or taken as control. After washing the monolayer in Hepes 
Tris buffer (HT-Buffer: 132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM d-Glucose, 
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HEPES 10 mM, pH was set to 7.4 using 1.5 M Tris in MQ, 37 °C) HT-buffer containing 100 µM 
ASP+ was added and the cells were incubated for 15 min at 37 °C. Intracellular uptake of the 
fluorescent compound (dimethylamino)styryl)-N-methylpyridinium-iodide (ASP+) was measured using a 
Zeiss Apotome Fluorescence microscope. Images were recorded over a time period of 15 min, starting 
2 min after addition of 10 µM ASP+ to enable a good focus on the cellular monolayer (Zeiss 
Axiovision imaging software 4.7.2). Fluorescence intensity over time was quantified for at least 6 
individual cells for each condition, by plotting the Z-axis profile of the virtual stack using ImageJ 
software (ImageJ 1.46r, NIH, Bethesda, MA, USA). 
To enable high throughput evaluation of organic cation uptake following stimulation by ET-1, in 
combination with pharmacological modulation of the signaling pathway, a fluorescence reader based 
method was used. Matured cells, cultured in 12 wells plates (seeded at approx. 150,000 cells/well) 
were treated with fresh medium containing the test-compounds, inhibitor or control medium for the 
designated incubation period. Subsequently, the cells were washed with Hepes Tris buffer (pH 7.4). 
HT-buffer containing 10 µM ASP+ was added and the cells were incubated for 15 min at 37 °C. Next, 
the uptake was arrested by washing twice with ice-cold stop solution (0.5mM TPA in HT-buffer). 
Then, the cells were lysed for 30 min lysis buffer (0.05% w/v Saponin, 0.05% v/v triton in MilliQ) and the 
cell homogenate transferred to a 96 wells plate (Greiner). The fluorescence measurement was performed 
three times at 450–642nm VictorX multilabel plate reader (PerkinElmer, Waltham, MA, USA). 
2.6. Data Analysis 
Values are given as mean ± standard error of the mean. Fluorescence levels are normalized to the 
unexposed control samples after subtraction of the background fluorescence at baseline (t = 0). Mean 
values were considered to be significantly different when p < 0.05 using a one-way ANOVA followed 
by Dunnett’s multiple comparison test. Software used for statistical analysis was GraphPad Prism 
(version 5.00 for Windows; GraphPad Software, San Diego, CA, USA). 
3. Results and Discussion  
3.1. Various Cationic Uremic Toxins Induce IL-6, IL-8, TNFα and ET-1 Production by ciPTEC 
Production of the pro-inflammatory cytokines IL-6, IL-8 and TNFα by ciPTEC was measured in 
culture supernatant after exposure to a selection of cationic UTs (Figure 1a), which have previously 
been shown to interfere with tubular organic cation uptake. To assess the potencies of the individual 
UTs on cytokine production, ciPTEC were exposed to 100 µM of guanidine, cadaverine, putrescine, 
methylguanidine, spermine, spermidine or 10 µM of acrolein for 24 h. Acrolein was used at a lower 
concentration to prevent severe cytotoxicity [2]. Average baseline IL-6, IL-8 and TNF-α production by 
ciPTEC over 24 h were determined to be 51 ± 5.4 ng·mL−1, 79 ± 37 ng·mL−1 and 227 ± 35 pg·mL−1 
respectively. Compared to controls, IL-6 production increased significantly after stimulation by 
guanidine (126 ± 5%, p < 0.05), putrescine (126 ± 1%, p < 0.05), spermine (141 ± 2%, p < 0.001) and 
spermidine (142 ± 6%, p < 0.001). IL-8 production was stimulated by 100 µM of cadaverine (135 ± 
15%, p < 0.01), methylguanidine (134 ± 9%, p < 0.001) spermine (128 ± 12%, p < 0.01) and 
spermidine (145 ± 25%, p < 0.001). We also detected a significant rise in TNFα production after exposure 
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to 100 µM of putrescine (126 ± 1%, p < 0.05) and methylguanidine (130 ± 7%, p < 0.05; Figure 1a). 
Lipopolysaccharide (LPS, 10 µg·mL−1) was used as a positive control, which caused a significant increase 
in IL-6 (181 ± 14%, p < 0.001), IL-8 (282 ± 23%, p < 0.001) and TNFα levels (284 ± 9%, p < 0.001). 
When ciPTEC were exposed to a mixture of the selected cationic UTs (i.e., toxin concentrations 
corresponding to those found in uremic patients, see Methods Section for actual concentrations used; 
Figure 1b) for 24 h, a significant increase in IL-6 (117 ± 3%, p < 0.001) and IL-8 (122 ± 3%, p < 0.001) 
cytokine levels could be detected. When increasing the UT mixture to 10-fold the concentrations 
reported in patients, IL-6 and IL-8 levels increased even further, until 150 ± 2% and 127 ± 2% (p < 0.001) 
when compared to control cells, respectively. TNFα levels did not rise upon exposure to these  
uremic mixtures. 
 
Figure 1. TNFα, IL-6, IL-8 and ET-1 excretions by ciPTEC after exposure to cationic UTs. 
(a) TNFα, IL-6 and IL-8 excretion was measured 24 h after incubation of ciPTEC with 10 
µM acrolein, 100 µM of guanidine, cadaverine, putescine, methylguanidine, spermine, 
spermidine, or 10 µg·mL−1 LPS; (b) TNFα, IL-6 and IL-8 excretion was measured 24 h after 
incubation of ciPTEC with a mixture of above stated cationic UTs, corresponding to one-fold 
or 10-fold the levels reported in uremic patients; (c) ET-1 production by ciPTEC after 24 h of 
incubation with the mixture of cationic UTs or 10 µg/mL LPS. Data are expressed as the 
percentage of cytokines or ET-1 produced compared with untreated cells, set at 100%. 
Results are shown as normalized means ± SEM. For each condition at least three experiments 
were performed in triplicate (* p < 0.05, ** p < 0.01, *** p < 0.001, ANOVA). 
Production of the vasoactive peptide and inflammatory mediator ET-1 by ciPTEC was measured in 
culture supernatant after exposure to the mixture of the selected cationic UTs for 24 h. Figure 1c 
depicts the ET-1 release by ciPTEC. Average baseline ET-1 production by ciPTEC over 24 h was 
determined to be 14.6 ± 4 pg·mL−1 (11 ± 4 pg·mg−1protein). Exposure to the one-fold and 10-fold 
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cationic UT mixture for 24 h increased ET-1 production by ciPTEC, up to 128 ± 7% (p < 0.01) and 
134.4 ± 5% (p < 0.001), respectively. Exposure of ciPTEC to the individual cationic uremic 
compounds for 24 h, did not lead to significantly affected ET-1 release (data not shown). Remarkably, 
LPS did not induce ET-1 production by ciPTEC. 
3.2. Differential Effect of ET-1 Exposures on Organic Cation Transport 
To investigate if ET-1 could affect the functionality of the organic cation transporters (OCT) 
present in ciPTEC, we measured the intracellular uptake of the fluorescent compound 4-(4-ASP+ after 
exposure to ET-1. A dose-response curve showed a significant increase in ASP+ uptake at concentrations of 
100 nM and 1 µM ET-1 (Figure S1). As a control, TPA was used which inhibited ASP uptake by 
approx. 70%. In Figure 2 representative fluorescence images (A) and their quantified fluorescent 
signals (B) are shown for the ASP+ uptake by ciPTEC in the presence or absence of 100 nM ET-1 
exposure. A significant increase in maximal uptake was observed after 24 h of incubation, while 30 
min of exposure diminished the uptake compared to unexposed cells. 
 
Figure 2. Changes in ASP+ uptake by ciPTEC in response to exposure to ET-1. CiPTEC 
were incubated for 30 min or 24 h with 100 nM ET-1 before measuring the intracellular 
uptake of the fluorescent cationic compound ASP+ (10 µM). (a) Representative confocal 
images of 24 h ET-1 exposed (top row), 30 min ET-1 exposed (middle row) or control 
cells (bottom row) taken at 2, 8 or 15 min after addition of ASP+; (b) ASP+ accumulation 
in cells was determined over the 15 min time period for 24 h ET-1 exposed (●), 30 min 
ET-1 exposed (▲) or control cells (■). Fluorescence intensity over time was quantified for 
at least six individual cells for each condition. Images were captured by real time imaging. 
Prior to addition of the fluorescent compound, brightfield images (panel A) were taken. 
The addition of the fluorescent substrate resulted in minor cell movement, thereby 
affecting cell positioning to some extent. 
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By using a fluorescent reader based method, more conditions were tested in a high throughput 
fashion (Figure 3a). Again, after 30 min of pre-incubation with 100 nM ET-1, a 23 ± 4% (p < 0.001) 
decrease in ASP+ uptake was measured. This effect was not observed after increasing the  
pre-incubation time to 3 or 6 h. However, after 24 h of pre-incubation, a 20 ± 5% (p < 0.001) increase 
in ASP+ uptake was observed. Addition of the ET-1 receptor inhibitor BQ-788 during the exposures 
normalized the ASP+ uptake levels for all time points (Figure 3b). 
In humans, OCT2 (SLC22A2) is considered one of the most important renal OCT [33]. We 
examined its mRNA expression levels after exposure to 100 nM ET-1 for 30 min or 24 h and 
compared these results to the control situation. Additionally, the expression levels of OCT1 and OCT3 
were examined as these are expressed in ciPTEC as well [2,34]. Exposure to ET-1 did not significantly 
alter OCT1, 2 or 3 expression levels for short or long term (data included as Figure S2). 
 
Figure 3. Regulatory effects on OCT mediated ASP+ uptake through ET-1 Receptor. Pre-
incubation of ciPTEC with 100 µM ET-1 for 30 min up to 24 h inhibits the cellular uptake 
of 10µM of the fluorescent substrate ASP+. (a) The effects of 100 μM ET-1 on steady state 
(15 min) ASP+ accumulation; (b) ASP+ accumulation of ciPTEC after pre-incubation with 
a combination of 100 nM ET-1 with the ET-B receptor inhibitor BQ788 (1 µM), which 
blocked the effect of ET-1 at all time points. Values are depicted as means ± SEM for at 
least three experiments performed in triplicate (* p < 0.05, ** p < 0.01, *** p < 0.001). 
3.3. iNOS Inhibition Attenuates the Inhibitory Effects of ET-1 Exposure on Organic Cation Uptake 
Previous studies demonstrated that ET-B receptor activation can initiate an NO mediated signaling 
pathway that regulates drug transport in the proximal tubule [24]. Therefore, we investigated if the 
differential regulation of intracellular organic cation uptake induced by ET-1, resulted from nitric 
oxide synthase (NOS) activation. ciPTEC were pre-incubated with 100 nM ET-1 in the absence or 
presence of the nonselective NOS‐inhibitor l‐arginine analogue N(G)‐monomethyl‐l‐arginine  
(L-NMMA). Figure 4a shows that L-NMMA alone did not influence ASP+ uptake by ciPTEC, but 
attenuated the ET-1 mediated down-regulation in ASP+ uptake at 30 min. This effect was not observed 
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after the 24 h pre-incubation period. Pre-incubation with the selective inducible NOS inhibitor AG in 
the presence or absence of ET-1 produced similar results, attenuating only the short-term ET-1 
mediated effect (Figure 4b). 
 
Figure 4. NOS-inhibition reverses the short-term action of ET-1 on ASP+ uptake. CiPTEC 
monolayers were incubated for 15 min in medium containing 10 µM ASP+ without or with 
pre-incubation with (a) 100 nM ET-1, 100 μM L-NMMA or ET-1 plus L-NMMA; (b) 100 nM 
ET-1, 100 μM aminoguanidine (AG) or ET-1 plus 100 µM AG. Subsequently, the reaction 
was stopped, the cells were lysed and the fluorescent signal was measured as described in 
the methods section. Values are presented as means ± SEM for at least three experiments 
performed in triplicate. (* p < 0.05, ** p < 0.01, *** p < 0.001). 
3.4. PKC Activation Restores Short-Term Organic Cation Uptake in ciPTEC after ET-1 Exposure 
Cyclic guanosine monophosphate (cGMP) activation was simulated by the addition of 1 µM of  
8-br-cGMP, a cell permeable analog of cGMP, which was previously identified as an important 
signaling molecule in ET-1 regulated MRP2 transport in the proximal tubule [35]. After pre-incubation 
of ciPTEC with 1 µM 8-Br-cGMP alone, the intracellular ASP+ levels did not differ from the control 
conditions (Figure 5a). Also, combining the pre-incubation to ET-1 exposure with 8-Br-cGMP could 
not prevent either the inhibitory effect on ASP+ uptake at 30 min, or the stimulation observed after 24 h. 
These results point towards an absence of protein kinase G and cGMP as signaling molecule in this 
ET-1-mediated pathway. Protein kinase C was stimulated by pre-incubation with the PKC activator  
sn-1,2-dioctanoyl glycerol (DOG), which is a cell permeable analog of the PKC-activating second 
messenger diacylglycerol (DAG). Pre-incubation of ciPTEC with 1 µM DOG alone did not alter ASP+ 
uptake compared to the non-exposed control situation (Figure 5b). Combining ET-1 and DOG during 
30 min of pre-incubation restored the ASP+ uptake by ciPTEC to the control situation. This effect of 
DOG was not observed after 24 h of ET-1 incubation, suggesting that two separate pathways regulate 
organic cation transport. 
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Figure 5. Kinase pathways on ciPTEC ASP+ uptake levels after exposure to ET-1. 
ciPTEC monolayers were incubated for 15 min in medium containing 10 µM ASP+ 
without or with pre-incubation with (a) 100 nM ET-1, 1 μM DOG or ET-1 plus DOG; (b) 
100 nM ET-1, 1 μM 8-br-cGMP or ET-1 plus 100µM 8-br-cGMP. Subsequently, the 
reaction was stopped, the cells lysed and the fluorescent signal was measured as described 
in the methods section. Values are expressed as means ± SEM for at least three 
experiments performed in triplicate. (* p < 0.05, ** p < 0.01, *** p < 0.001). 
3.5. Discussion 
The results of the present study indicate that exposure of human proximal tubule epithelial cells to 
cationic UTs leads to cytokine and ET-1 production by ciPTEC. We demonstrated that the production 
of IL-6, IL-8, and TNFα was stimulated by the exposure to high levels of individual cationic toxins, 
supporting the inflammatory response often observed in uremia. At clinically relevant concentrations, 
a mixture of these selected toxins induced the endogenous production of IL-6, IL-8 and ET-1. 
Additionally, ET-1 was identified as time-dependent regulator of organic cation uptake through 
interaction with the ET-B receptor. 
In patients suffering from renal failure, the accumulation of UTs was reported to be associated with 
the development of a chronic inflammatory state [9]. Various clinical studies have demonstrated a 
correlation between increasing IL-6, IL-8 and TNFα cytokine levels and reduced glomerular filtration 
rate [11,12]. Inefficient clearance of the inflammatory mediators in combination with increased 
cytokine production could cause these effects. The results of the present study confirm that exposure to 
a cationic uremic mixture of acrolein, spermine, spermidine, cadaverine, putrescine, guanidine and 
methylguanidine induced the production of IL-6 and IL-8 by using the human renal cell line ciPTEC.  
The observed increase in IL-6 and IL-8 production ranged from 26%–45%. When compared to the 
81%–182% increase in IL-6 and IL-8 release after LPS stimulation, this level could be considered 
modest. However, LPS is one of the most potent inducers of cytokine production. Patients suffering 
from ESRD were reported to show a 35% rise in IL-6 levels [11]. The local production of these 
cytokines in response to a uremic milieu can promote local profibrotic or inflammatory processes in-
vivo, since IL-6 production is associated with the induction of fibrotic gene expression, and IL-8 is a 
potent neutrophil chemoattractant [36,37]. Therefore, we could consider the 26%–45% increase in 
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production of IL-6 and IL-8 by proximal tubule epithelial cells clinically relevant. It is, however, 
important to take into account that our in vitro settings cannot be translated directly to the clinical 
situation, especially with regard to protein binding and intracellular solute concentrations. Not only are 
organic solutes often able to bind to human serum albumin, they can also interact with other proteins 
such as α1-acid glycoprotein and lipoproteins, and even red blood cells and platelets [38]. On the other 
hand, it is known that ESRD can affect systemic protein binding of drugs and endogenous compounds 
due to displacement [39–41]. Protein binding could, therefore, affect the free fraction of uremic solutes 
available to cells. Nevertheless, intracellular levels often easily exceed the free serum concentrations 
due to active uptake processes [42,43]. 
The absence of TNFα production by ciPTEC after exposure to the UT mixture contrasts with the 
effects of the individual compounds putrescine and methylguanidine. In the mixture, the 
concentrations of these compounds were much lower as compared to the experiments performed with 
the individual compounds, which might explain this effect. Additionally, TNFα is known to possess a 
very short half-life in whole blood [44], and low concentrations are reported to denature rapidly in 
culture medium at 37 °C [45,46]. Since ciPTEC were exposed for 24 h, the initial TNFα peak could 
have subsided before the measurement was performed. 
Many cytokines, including IL-6, are known to stimulate ET-1 production. Furthermore, the 
proximal tubule can endogenously produce ET-1 upon stimulation with various nephrotoxicants, as 
was previously demonstrated in non-human species [24,47,48]. Here we show that, next to the 
production of IL-6 and IL-8, the mixture of cationic UTs also promoted a modest ET-1 release by 
ciPTEC. The local production of ET-1 in the renal tubule has been recognized as an early response to 
tubular injury, and was identified as a key regulator of efflux transporters, MRP2 and  
P-gp [23,26,35,47–49]. In these studies, the threshold for ET-1 action on transporters was determined 
to be between 0.5 and 10 nM (1.25–24.9 ng·mL−1). In our study, the ET-1 release by ciPTEC was well 
below this threshold (Figure 1). The quantity of hormone released by ciPTEC is small, and much 
diluted by the cell culture medium. However, since the cells produce this compound endogenously, the 
threshold level could be reached in the direct vicinity of the cells. 
The results of the present study also demonstrate that next to the regulation of MRP2 and P-gp, ET-1 
can differentially regulate cation uptake in ciPTEC. Because ET-1 is a hydrophilic compound, surface 
receptors are necessary to regulate intracellular responses to the peptide. The regulatory effects of ET-
1 on the OCT-mediated ASP+ uptake were clearly mediated through the action of the ET-B-receptor, since 
the addition of the ET-B-receptor blocker BQ-788 ameliorated both effects observed after 30 min and 24 h. 
The inhibition of OCT-mediated ASP+ transport by ET-1 after 30 min is in line with earlier reports. 
Terlouw et al. previously hypothesized that the reduction in efflux activity by transporters could 
protect the cell form injury after exposure to a nephrotoxic substance by saving ATP for more 
immediate processes that are necessary for cell survival [24,48]. Although the reduction in ASP+ 
uptake by ciPTEC after 30 min suggests a similar protective mechanism for OCT, the reduced influx is 
unlikely to serve as an ATP saving mechanism. Organic cation uptake processes are mostly mediated 
by polyspecific solute carriers like OCT2 (SLC-22 family), which are membrane potential and 
substrate concentration gradient dependent, and therefore function as facilitated diffusion carriers for 
organic cations, but are independent of proton gradients. In addition, two other types of apically 
expressed transporters might be involved, viz. the Carnitine/Organic Cation Transporters OCTN1 and 
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OCTN2 (SLC22A4 and SLC22A5 [50,51]) and the proton antiporters, MATE1 and MATE2k (multi-
antimicrobial extrusion proteins). Schmidt-Lauber et al. reported active uptake of ASP+ through 
OCTN1 and MATE1 in transporter-transfected HEK293 cells and human synovial fibroblasts 
(hRASF) [52]. In ciPTEC, the exact role of these transport proteins in the uptake of cationic organic 
substrates, such as ASP+ or uremic retention solutes, is yet unclear. Future studies should be directed to 
further elucidate their role. 
Solute carriers do not rely directly on ATP binding or hydrolysis [53,54]. Based on our results, we 
suggest that the short-term reduction in organic cation influx by ET-1 signaling provides protection by 
minimizing intracellular accumulation of potentially toxic compounds. In acute situations, this would 
reduce intracellular damage until other clearance processes are activated to handle the toxic threat. On 
the other hand, the increased influx transport observed after 24 h was unexpected. This observation 
could not be linked to increased mRNA levels of OCT2 neither OCT1 or OCT3, of which detection on 
mRNA level in ciPTEC was remarkable, since they are generally considered of less importance in 
human kidney [33,34] (Figure S2). We cannot exclude the involvement of another important 
mechanism in the short-term regulation of transporter activity known as endocytic membrane retrieval, 
or insertion as suggested previously [55,56]. This mechanism has also been described in the short-term 
regulation of the proximal tubular type IIa Na-Pi cotransporter, and the pH-regulated insertion of  
H+-ATPases in the proximal tubule [57–60]. Furthermore, rapid insertion of MRP2 in response to 
tubulo toxic insults has been described [26,61]. If OCT functionality is regulated by such rapid 
dynamic endocytic retrieval or insertion processes, the regulation depends on an intracellular vesicular 
pool of transporters, and its regulation will therefore not directly affect mRNA expression levels. The 
development of specific antibodies directed at the human organic cation transporters, together with 
immunocytochemistry or protein expression studies, could in the future provide more insight into the 
involvement of the regulatory mechanisms of organic cation uptake in ciPTEC. Furthermore, post-
translational modifications, such as phosphorylation, could affect transporter activity. In the 
intracellular loops of the (human) SLC-22 family, several potential phosphorylation sites have been 
identified [62]. For rOCT1, phosphorylation events are known to stimulate conformational changes at 
the substrate binding site, thereby increasing the affinity for its substrates [63]. In various studies 
focusing on ASP+ uptake in rabbit or human models, PKC stimulation was found to either induce or 
inhibit substrate uptake, depending on the species [64]. 
In ciPTEC, PKC stimulation by DOG in combination with ET-1 restored cation uptake after 30 min 
of pre-incubation. These observations suggest that PKC activation in ciPTEC stimulates organic cation 
uptake, however, this is in contrast to previous studies with hOCT2-HEK293 cells and isolated human 
proximal tubules [55,64]. The reason for this discrepancy is unclear, but considering the many 
intracellular processes affected by PKC this may suggest that multiple regulatory pathways  
are involved. Still, the findings of the present study are in agreement with the known interaction 
between ET-1 and the protein kinase pathway in the regulation of other renal transporters (viz. MRP2 
and P-gp) [23,65,66]. In killifish renal proximal tubules, dogfish shark salt glands and rat  
brain capillaries, ET-1 also reduced MRP2 or P-gp-mediated transport by stimulating the PKC 
pathway [23,65,66]. It would therefore be interesting to evaluate in future studies how ET-1 
production by ciPTEC would affect the transport by MRP2 or P-gp in this cell model. 
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Next to the PKC pathway, our results demonstrated that inhibition of iNOS by AG or L-NMMA 
restored ASP+ uptake at 30 min after ET-1 exposure. In the human proximal tubule, iNOS is 
constitutively expressed [67,68]. It mediates the regulation of local inflammatory responses, following 
cytokine production during endotoxemia, or after exposure to nephrotoxicants [47,48]. Similar to the 
iNOS induced effects observed in the present study, Heemskerk et al. demonstrated a reduction in 
OCT1 and OCT2 uptake transport during acute endotoxemia, while the functional expression of the 
efflux transporters MRP2 and P-gp, increased [25,69]. Therefore, iNOS is considered an important 
player in the regulation of the short-term tubular response to external assaults. These short-term effects 
of the inflammatory mediator ET-1 on the regulation proximal tubular cation uptake could provide 
clues on possible pathways involved in acute kidney injury. 
Though numerous studies have investigated the mechanisms involved in renal proximal tubular 
transport, the mechanisms behind these regulatory pathways is often analyzed within relatively short 
time frames. We observed a time-dependent ET-B receptor mediated effect of ciPTEC exposure to ET-1, 
leading to an increased cellular uptake of cationic substances. The mechanisms behind this long-term 
(24 h) regulation could not be explained by the known NO, PKC or cGMP mediated pathways. These 
observations are reminiscent of both the biphasic and NO-independent pathways that were described 
for the efflux transporter P-gp [70,71], for which a second pathway, next to NO mediated regulation, 
was identified involving activation of Toll Like Receptor 4 and translocation of NF-κB. Further 
research would be warranted to investigate this pathway in the regulation of proximal tubular organic 
cation uptake. Investigating the increase in substrate uptake following long term ET-1 exposure might 
provide clues about possible treatment strategies to promote renal secretory clearance in uremia, or 
shed further light on protective mechanisms of the renal proximal tubule. 
In conclusion, our findings implicate that cationic UTs can directly induce the local production of 
inflammatory cytokines and ET-1. Furthermore, ET-1 exposure was found to enable regulation of 
organic cation uptake by proximal tubule cells. These findings might suggest that systemic 
accumulation of UTs in patients suffering from CKD could influence renal tubular clearance processes 
through local production of inflammatory or vasoactive mediators. However, further studies on OCT 
regulation and functionality in response to UT exposure are required to elucidate the exact processes 
that connect these events. 
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